Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 13.7 USD -1.23% Market Closed
Market Cap: 973.4m USD
Have any thoughts about
Zymeworks Inc?
Write Note

P/E
Price to Earnings

-8.7
Current
-1.7
Median
23.9
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-8.7
=
Market Cap
978.2m USD
/
Net Income
-112.5m USD
All Countries
Close
Earnings Growth
US
Zymeworks Inc
NASDAQ:ZYME
Average P/E: 56.8
Negative Multiple: -8.7
N/A
US
Abbvie Inc
NYSE:ABBV
68
406%
US
Amgen Inc
NASDAQ:AMGN
54.9
74%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -250.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
105.1
71%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493.2 N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
21.5
56%
AU
CSL Ltd
ASX:CSL
34.5
64%
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -468.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.3 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-12.2
2-Years Forward
P/E
-11.6
3-Years Forward
P/E
-13.7

See Also

Discover More